Welcome to our dedicated page for Dyne Therapeutics news (Ticker: DYN), a resource for investors and traders seeking the latest updates and insights on Dyne Therapeutics stock.
Dyne Therapeutics, Inc. (Nasdaq: DYN) is a clinical-stage biopharmaceutical company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. The DYN news feed highlights company announcements related to its neuromuscular pipeline, corporate strategy and financial position.
News coverage for Dyne commonly includes updates on its lead clinical programs, zeleciment rostudirsen (z-rostudirsen, DYNE-251) for Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping and zeleciment basivarsen (z-basivarsen, DYNE-101) for myotonic dystrophy type 1 (DM1). Investors can follow topline and long-term data readouts from the Phase 1/2 DELIVER and ACHIEVE trials, including biomarker results, functional endpoints, safety and tolerability findings, and regulatory milestones such as Breakthrough Therapy, Fast Track, Rare Pediatric Disease and Orphan Drug designations.
The DYN news stream also features information on Dyne’s preclinical programs in facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease, presentations at scientific and investor conferences, and corporate developments such as public offerings of common stock, loan agreements and board appointments. Periodic financial results and business updates provide additional context on cash runway, planned regulatory submissions and the company’s preparation for potential commercialization of its neuromuscular therapies.
By monitoring this page, readers can review Dyne’s press releases on clinical progress, regulatory interactions, financing transactions and conference presentations in one place. This historical record of company communications helps investors, analysts and other stakeholders understand how Dyne’s FORCE platform, pipeline and corporate activities are evolving over time.
Dyne Therapeutics (Nasdaq: DYN) announced it will showcase new preclinical data on its myotonic dystrophy type 1 (DM1) program at the American Society of Gene & Cell Therapy meeting, running from May 11-14, 2021. Key presentations include a scientific symposium and an oral presentation detailing the effectiveness of their FORCE™ platform in knocking down toxic RNA in DM1 models. A live webcast featuring expert Dr. Charles Thornton will follow on May 14, 2021, at 4 p.m. ET to discuss the DM1 program and its challenges. The archived webcast will be accessible for 90 days.
Dyne Therapeutics reported significant advancements in its muscle disease therapeutics, particularly in its DM1, DMD, and FSHD programs. The company announced a net loss of $28.6 million for Q4 2020 and $59.4 million for the full year, with cash reserves of $345.3 million expected to last into H2 2024. Recent preclinical data showed robust RNA knockdown capabilities in their DM1 candidate. Additionally, leadership enhancements and a successful public offering raised over $550 million in 2020, supporting ongoing clinical developments.
Dyne Therapeutics (DYN) has appointed Dr. Wildon Farwell as Chief Medical Officer, bringing extensive experience in developing oligonucleotide therapies. Previously with Biogen, he played crucial roles in the approval of SPINRAZA and led the development of tofersen. His expertise is expected to enhance Dyne's clinical strategy as it advances programs for myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. This leadership change underscores Dyne's commitment to transforming care for rare muscle diseases.
Dyne Therapeutics has appointed Ashish Dugar as Senior Vice President and Global Head of Medical Affairs. Dr. Dugar brings over 20 years of experience in medical affairs and drug development, previously holding significant roles at Sarepta Therapeutics, Intra-Cellular Therapies, and Roche. His expertise includes building medical affairs organizations and a focus on rare muscle diseases. Dyne's CEO highlighted Dr. Dugar's critical role in advancing the company's therapeutic programs, particularly in muscle diseases using the proprietary FORCE™ platform.
Dyne Therapeutics (Nasdaq: DYN) announced a public offering of 6,000,000 shares at $28.00 each, with potential gross proceeds of approximately $168 million. The offering includes a 30-day option for underwriters to purchase an additional 900,000 shares. The closing is set for January 25, 2021, subject to customary conditions. The proceeds will support Dyne's development of innovative therapeutics for muscle diseases driven by genetics, utilizing its proprietary FORCE™ platform.
Dyne Therapeutics (Nasdaq: DYN) announced significant preclinical data revealing effective RNA knockdown of toxic DMPK associated with myotonic dystrophy type 1 (DM1). Utilizing its FORCE™ platform and an innovative mouse model, the company achieved up to 60% reduction of toxic DMPK RNA in muscle tissues. This progress reinforces the potential for targeted therapies aimed at DM1, with IND submissions for DM1, DMD, and FSHD expected between Q4 2021 and Q4 2022. The advancements align with Dyne's goal of addressing unmet medical needs in muscle diseases.
Dyne Therapeutics (DYN) announced that CEO Joshua Brumm and CSO Romesh Subramanian will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 10:00 a.m. ET. The presentation will focus on the company's dedication to developing innovative therapeutics for genetically driven muscle diseases using its proprietary FORCE™ platform.
A live webcast will be accessible on the company's Investors & Media website, with a replay available for 90 days post-presentation.
Dyne Therapeutics (Nasdaq: DYN) announced its participation in several upcoming virtual investor conferences. CEO Joshua Brumm and Chief Scientific Officer Romesh Subramanian will host fireside chats at these events:
- Stifel 2020 Virtual Healthcare Conference on Nov 16, 2020, at 10:00 a.m. ET
- Jefferies Virtual London Healthcare Conference on Nov 19, 2020, at 7:55 a.m. ET
- Piper Sandler 32nd Annual Virtual Healthcare Conference, available on Nov 23, 2020
Webcast recordings will be accessible on Dyne's website for 90 days following each presentation.
Dyne Therapeutics, Inc. (Nasdaq: DYN) reported third quarter 2020 financial results, highlighting a $268 million IPO and $116 million Series B financing to fund its myotonic dystrophy type 1 and Duchenne muscular dystrophy programs. Cash and cash equivalents rose to $379.6 million from $14.6 million at year-end 2019. R&D expenses were $9.7 million, up from $3.0 million in Q3 2019. Despite a net loss of $13.9 million, the company is on track for IND submissions by late 2021 to late 2022, aiming for proof-of-concept data in its lead programs.
Dyne Therapeutics, Inc. (Nasdaq: DYN) has successfully closed its initial public offering, selling 14,089,314 shares at $19.00 per share, raising approximately $268 million in gross proceeds. This includes 1,837,736 shares from underwriters exercising their option to purchase additional shares. The stock began trading on the Nasdaq Global Select Market on September 17, 2020. J.P. Morgan, Jefferies, Piper Sandler, and Stifel acted as joint book-running managers for the offering.